BridgeMD
New treatment option for Heart Failure
Official title the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
ClinicalTrials.gov ID: NCT07692256
What this study is testing
What is Empagliflozin (EMPA)?
Empagliflozin (EMPA) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for heart failure.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- the study to investigate the efficacy of empagiflozin in pediatric heart failure
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 18
You may be able to join if
- Pediatrics (aged 1months-18 years)
- Confirmed HF diagnosis: HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or...
- Class III or IV of ROSS classification or BNP level more than 300 pg/mL
You likely can't join if
- Pediatric with chronic kidney failure
- Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI).
- patients with eGFR \<60 mL/minute/1.73 m2 will be excluded.
- Patients with contraindication to empagliflozin usage which include
- eGFR \<30 mL/minute/1.73 m2
- Hypersensitivity (eg, angioedema) to empagliflozin
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Cairo Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 month to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Cairo Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.